These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23141996)

  • 1. Silymarin for diabetic nephropathy: the challenges of botanical product research.
    Meyers CM; Briggs JP
    Am J Kidney Dis; 2012 Dec; 60(6):887-9. PubMed ID: 23141996
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy.
    Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1993; 21(3):126-32. PubMed ID: 8299855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren and dual therapy in type 2 diabetes mellitus.
    Ingelfinger JR
    N Engl J Med; 2008 Jun; 358(23):2503-5. PubMed ID: 18525047
    [No Abstract]   [Full Text] [Related]  

  • 6. Viper venom for diabetic nephropathy.
    Caramori ML
    Kidney Int; 2012 Apr; 81(7):615-6. PubMed ID: 22419043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch S
    Int J Clin Pract; 2010 Sep; 64(10):1337-40. PubMed ID: 20716140
    [No Abstract]   [Full Text] [Related]  

  • 8. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the renin-angiotensin system: is more better?
    Anderson S; Komers R
    Kidney Int; 2009 Jan; 75(1):12-4. PubMed ID: 19092813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
    Guo LL; Pan Y; Jin HM
    Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of the renin-angiotensin system in type 2 diabetes. New significant results concerning type 2 diabetes and renal disease].
    Mogensen CE
    Ugeskr Laeger; 2001 Oct; 163(40):5488. PubMed ID: 11601112
    [No Abstract]   [Full Text] [Related]  

  • 14. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
    Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
    Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acarbose on blood glucose and proteinuria in patients with diabetic nephropathy.
    Tomino Y; Shirato I; Horikoshi S; Fukui M; Yamaguchi Y; Yokomatsu M; Ebihara I; Shimada N; Hishiki T; Hirano K; Rinno H; Shiota J; Kuramoto T
    Nephron; 2000 Jun; 85(2):190. PubMed ID: 10867532
    [No Abstract]   [Full Text] [Related]  

  • 19. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.
    Voroneanu L; Siriopol D; Dumea R; Badarau S; Kanbay M; Afsar B; Gavrilovici C; Covic A
    Int Urol Nephrol; 2017 Dec; 49(12):2195-2204. PubMed ID: 28948420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.